Faeth Therapeutics (FTH) Share-based Compensation (2020 - 2026)

Faeth Therapeutics (FTH) has reported Share-based Compensation for 7 consecutive years, with $62.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Share-based Compensation rose 20959.83% year-over-year to $62.2 million; the trailing twelve-month figure through Jun 2026 stood at $62.2 million (up 20959.83% YoY), and the FY2025 full-year result was $1.3 million, down 59.36% from the prior year.
• Share-based Compensation rose to $62.2 million in Q2 2026 per FTH's latest filing, from $57.4 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $62.2 million in Q2 2026 and bottomed at $295000.0 in Q4 2025.
• Historically, Share-based Compensation has averaged $9.2 million across 5 years, with a median of $3.4 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Share-based Compensation sank 93.61% in 2025, then soared 20959.83% in 2026.
• Over 5 years, Share-based Compensation stood at $1.4 million in 2022, then dropped by 21.52% to $1.1 million in 2023, then tumbled by 64.39% to $391000.0 in 2024, then slipped by 24.55% to $295000.0 in 2025, then jumped by 20984.75% to $62.2 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $62.2 million, $57.4 million, and $295000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.